Document:

Exhibit 10.6

    

    

    INDEMNITY AGREEMENT

    

    

    THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of January 29, 2021, by and between FORTISTAR SUSTAINABLE
      SOLUTIONS CORP., a Delaware corporation (the “Company”), and the undersigned (“Indemnitee”).

    

    

    RECITALS

    

    

    WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided with
      adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of such corporations;

    

    

    WHEREAS, the Board of Directors of the Company (the “Board”) has determined that, in order to attract and retain
      qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance
      has been a customary and widespread practice among publicly traded corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher
      premiums and with more exclusions. At the same time, directors, officers and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things,
      matters that traditionally would have been brought only against the Company or business enterprise itself. The Amended and Restated Certificate of Incorporation (the “Charter”) and the
      Bylaws of the Company require indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification pursuant to applicable provisions of the Delaware General Corporation Law (“DGCL”). The Charter, Bylaws and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and
      members of the Board, officers and other persons with respect to indemnification, hold harmless, exoneration, advancement and reimbursement rights;

    

    

    WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;

    

    

    WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company’s stockholders and that
      the Company should act to assure such persons that there will be increased certainty of such protection in the future;

    

    

    WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, hold harmless, exonerate and to advance expenses on behalf of, such
      persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so protected against liabilities;

    

    

    WHEREAS, this Agreement is a supplement to and in furtherance of the Charter and Bylaws of the Company and any resolutions adopted pursuant thereto, and shall not be deemed a
      substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and

    

    

    WHEREAS, Indemnitee may not be willing to serve as an officer or director, advisor or in another capacity without adequate protection, and the Company desires Indemnitee to serve
      in such capacity.  Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he or she be so indemnified;

    
      
        

    

    
    

    

    NOW, THEREFORE, in consideration of the premises and the covenants contained herein and subject to the provisions of the letter agreement dated as of January 29, 2021 between the Company and Indemnitee pursuant to the Underwriting Agreement among the Company and the representatives of the underwriters named therein in connection with the Company’s initial public offering, the
      Company and Indemnitee do hereby covenant and agree as follows:

    

    

    TERMS AND CONDITIONS

    

    

    1.          SERVICES TO THE COMPANY.  In consideration of the Company’s covenants and obligations hereunder, Indemnitee will serve or continue to serve as an officer,
      director, advisor, key employee or in any other capacity of the Company, as applicable, for so long as Indemnitee is duly elected, appointed or retained or until Indemnitee tenders his or her resignation or until Indemnitee is removed.

    

    

    2.          DEFINITIONS.  As used in this Agreement:

    

    

    2.1.          References to “agent” shall mean any person who is or was a director, officer or employee of the Company or a subsidiary of the Company or other
      person authorized by the Company to act for the Company, to include such person serving in such capacity as a director, officer, employee, advisor, fiduciary or other official of another corporation, partnership, limited liability company, joint
      venture, trust or other enterprise at the request of, for the convenience of, or to represent the interests of the Company or a subsidiary of the Company.

    

    

    2.2.          The terms “Beneficial Owner” and “Beneficial Ownership” shall have the meanings set
      forth in Rule 13d-3 promulgated under the Exchange Act (as defined below) as in effect on the date hereof.

    

    

    2.3.          A “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:

    

    

    2.3.1.          Acquisition of Stock by Third Party.  Other than an affiliate of FSSC Sponsor LLC (the “Sponsor”), any Person (as defined below) is or
      becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined voting power of the Company’s then outstanding securities entitled to vote generally in the election of
      directors, unless (1) the change in the relative Beneficial Ownership of the Company’s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of
      directors, or (2) such acquisition was approved in advance by the Continuing Directors (as defined below) and such acquisition would not constitute a Change in Control under part 2.3.3 of this definition;

    

    

    2.3.2.          Change in Board of Directors.  Individuals who, as of the date hereof, constitute the Board, and any new director whose election by the Board or nomination for election by the Company’s
      stockholders was approved by a vote of at least two thirds of the directors then still in office who were directors on the date hereof or whose election or nomination for election was previously so approved (collectively, the “Continuing Directors”), cease for any reason to constitute at least a majority of the members of the Board;

    

    

    2.3.3.          Corporate Transactions.  The effective date of a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination, involving the Company and one or
      more businesses (a “Business Combination”), in each case, unless, following such Business Combination:  (1) all or substantially all of the individuals and entities who were the Beneficial
      Owners of securities entitled to vote generally in the election of directors immediately prior to such Business Combination beneficially own, directly or indirectly, more than 51% of the combined voting power of the then outstanding securities of the
      Company entitled to vote generally in the election of directors resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company’s
      assets either directly or through one or more Subsidiaries (as defined below)) in substantially the same proportions as their ownership immediately prior to such Business Combination, of the securities entitled to vote generally in the election of
      directors; (2) other than an affiliate of the Sponsor, no Person (excluding any corporation resulting from such Business Combination) is the Beneficial Owner, directly or indirectly, of fifteen percent (15%) or more of the combined voting power of
      the then outstanding securities entitled to vote generally in the election of directors of the surviving corporation except to the extent that such ownership existed prior to the Business Combination; and (3) at least a majority of the Board of
      Directors of the corporation resulting from such Business Combination were Continuing Directors at the time of the execution of the initial agreement, or of the action of the Board of Directors, providing for such Business Combination;

    
      2

      
        

    

    

    

    2.3.4.          Liquidation.  The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement or series of agreements for the sale or disposition by the Company of all or
      substantially all of the Company’s assets, other than factoring the Company’s current receivables or escrows due (or, if such stockholder approval is not required, the decision by the Board to proceed with such a liquidation, sale, or disposition in
      one transaction or a series of related transactions); or

    

    

    2.3.5.          Other Events.  There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or any successor thereof) (or a response to
      any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement.

    

    

    2.4.          “Corporate Status” describes the status of a person who is or was a director, officer, trustee, general partner, manager, managing member,
      fiduciary, employee or agent of the Company or of any other Enterprise (as defined below) which such person is or was serving at the request of the Company.

    

    

    2.5.          “Delaware Court” shall mean the Court of Chancery of the State of Delaware.

    

    

    2.6.          “Disinterested Director” shall mean a director of the Company who is not and was not a party to the Proceeding (as defined below) in respect of
      which indemnification is sought by Indemnitee.

    

    

    2.7.          “Enterprise” shall mean the Company and any other corporation, constituent corporation (including any constituent of a constituent) absorbed in a
      consolidation or merger to which the Company (or any of its wholly owned subsidiaries) is a party, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the
      request of the Company as a director, officer, trustee, general partner, manager, managing member, fiduciary, employee or agent.

    

    

    2.8.          “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

    

    

    2.9.          “Expenses” shall include all direct and indirect costs, fees and expenses of any type or nature whatsoever, including, without limitation, all
      attorneys’ fees and costs, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, fees of private investigators and professional advisors, duplicating costs, printing and binding costs, telephone charges, postage,
      delivery service fees, fax transmission charges, secretarial services and all other disbursements, obligations or expenses in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness
      in, settlement or appeal of, or otherwise participating in, a Proceeding (as defined below), including reasonable compensation for time spent by Indemnitee for which he or she is not otherwise compensated by the Company or any third party.  Expenses
      also shall include Expenses incurred in connection with any appeal resulting from any Proceeding (as defined below), including without limitation the principal, premium, security for, and other costs relating to any cost bond, supersede as bond, or
      other appeal bond or its equivalent.  Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.

    

    

    2.10.          References to “fines” shall include any excise tax assessed on Indemnitee with respect to any employee benefit plan; references to “serving at
      the request of the Company” shall include any service as a director, officer, employee, agent or fiduciary of the Company which imposes duties on, or involves services by, such director, officer, employee, agent or fiduciary with respect to an
      employee benefit plan, its participants or beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan, Indemnitee
      shall be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement.

    

    

    

    

    2.11.          “Independent Counsel” shall mean a law firm or a member of a law firm with significant experience in matters of corporate law and that neither
      presently is, nor in the past five years has been, retained to represent:  (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other
      indemnitees under similar indemnification agreements); or (ii) any other party to the Proceeding (as defined below) giving rise to a claim for indemnification hereunder.  Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an
      action to determine Indemnitee’s rights under this Agreement.

    
      3

      
        

    

    

    

    2.12.          The term “Person” shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act as in effect on the date hereof; provided,
      however, that “Person” shall exclude:  (i) the Company; (ii) any Subsidiaries (as defined below) of the Company; (iii) any employment benefit plan of the Company or of a Subsidiary (as defined below) of the Company or of any corporation owned,
      directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company; and (iv) any trustee or other fiduciary holding securities under an employee benefit plan of the Company or
      of a Subsidiary (as defined below) of the Company or of a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.

    

    

    2.13.          The term “Proceeding” shall include any threatened, pending or completed action, suit, arbitration, mediation, alternate dispute resolution
      mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil (including intentional or unintentional tort claims),
      criminal, administrative, or investigative or related nature, in which Indemnitee was, is, will or might be involved as a party or otherwise by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action
      (or failure to act) taken by him or her or of any action (or failure to act) on his or her part while acting as a director or officer of the Company, or by reason of the fact that he or she is or was serving at the request of the Company as a
      director, officer, trustee, general partner, manager, managing member, fiduciary, employee or agent of any other Enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which
      indemnification, reimbursement, or advancement of expenses can be provided under this Agreement.

    

    

    2.14.          The term “Subsidiary,” with respect to any Person, shall mean any corporation, limited liability company, partnership, joint venture, trust or
      other entity of which a majority of the voting power of the voting equity securities or equity interest is owned, directly or indirectly, by that Person.

    

    

    3.          INDEMNITY IN THIRD-PARTY PROCEEDINGS.

    

    

    To the fullest extent permitted by applicable law, the Company shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this Section 3 if Indemnitee was, is, or is threatened to be made, a party to or a
      participant (as a witness or otherwise) in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor.  Pursuant to this Section 3, Indemnitee shall be indemnified, held harmless and
      exonerated against all Expenses, judgments, liabilities, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines,
      penalties and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she
      reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding, had no reasonable cause to believe that his or her conduct was unlawful.

    

    

    4.          INDEMNITY IN PROCEEDINGS BY OR IN THE RIGHT OF THE COMPANY.

    

    

    To the fullest extent permitted by applicable law, the Company shall indemnify, hold harmless and exonerate Indemnitee in accordance with the provisions of this Section 4 if Indemnitee was, is, or is threatened to be made, a party to or a
      participant (as a witness or otherwise) in any Proceeding by or in the right of the Company to procure a judgment in its favor.  Pursuant to this Section 4, Indemnitee shall be indemnified, held harmless and exonerated against all Expenses
      actually and reasonably incurred by him or her or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed
      to the best interests of the Company.  No indemnification, hold harmless or exoneration for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a
      court to be liable to the Company, unless and only to the extent that any court in which the Proceeding was brought or the Delaware Court shall determine upon application that, despite the adjudication of liability but in view of all the
      circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification, to be held harmless or to exoneration.

    
      4

      
        

    

    

    

    5.          INDEMNIFICATION FOR EXPENSES OF A PARTY WHO IS WHOLLY OR PARTLY SUCCESSFUL.

    

    

    Notwithstanding any other provisions of this Agreement except for Section 27, to the extent that Indemnitee was or is a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any
      claim, issue or matter therein, in whole or in part, the Company shall, to the fullest extent permitted by applicable law, indemnify, hold harmless and exonerate Indemnitee against all Expenses actually and reasonably incurred by him or her in
      connection therewith.  If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall, to the fullest extent
      permitted by applicable law, indemnify, hold harmless and exonerate Indemnitee against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection with each successfully resolved claim, issue or matter.  If
      Indemnitee is not wholly successful in such Proceeding, the Company also shall, to the fullest extent permitted by applicable law, indemnify, hold harmless and exonerate Indemnitee against all Expenses reasonably incurred in connection with a claim,
      issue or matter related to any claim, issue, or matter on which Indemnitee was successful.  For purposes of this Section 5 and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or
      without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

    

    

    6.          INDEMNIFICATION FOR EXPENSES OF A WITNESS.

    

    

    Notwithstanding any other provision of this Agreement except for Section 27, to the extent that Indemnitee is, by reason of his or her Corporate Status, a witness in any Proceeding to which Indemnitee is not a party, he or she shall, to
      the fullest extent permitted by applicable law, be indemnified, held harmless and exonerated against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith.

    

    

    7.          ADDITIONAL INDEMNIFICATION, HOLD HARMLESS AND EXONERATION RIGHTS.

    

    

    7.1.          Notwithstanding any limitation in Sections 3, 4, or 5, except for Section 27, the Company shall, to the fullest extent permitted by applicable law, indemnify, hold harmless
      and exonerate Indemnitee if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines, penalties
      and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually and reasonably incurred by
      Indemnitee in connection with the Proceeding.  No indemnification, hold harmless or exoneration rights shall be available under this Section 7.1 on account of Indemnitee’s conduct which constitutes a breach of Indemnitee’s duty of loyalty to
      the Company or its stockholders or is an act or omission not in good faith or which involves intentional misconduct or a knowing violation of the law.

    

    

    7.2.          Notwithstanding any limitation in Sections 3, 4, 5 or 7.1, except for Section 27, the Company shall, to the fullest extent permitted by applicable law, indemnify,
      hold harmless and exonerate Indemnitee if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments,
      fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually and
      reasonably incurred by Indemnitee in connection with the Proceeding.

    

    

    8.          CONTRIBUTION IN THE EVENT OF JOINT LIABILITY.

    

    

    8.1.          To the fullest extent permissible under applicable law, if the indemnification, hold harmless and/or exoneration rights provided for in this Agreement are unavailable to Indemnitee in whole or in part for
      any reason whatsoever, the Company, in lieu of indemnifying, holding harmless or exonerating Indemnitee, shall pay, in the first instance, the entire amount incurred by Indemnitee, whether for judgments, liabilities, fines, penalties, amounts paid or
      to be paid in settlement and/or for Expenses, in connection with any Proceeding without requiring Indemnitee to contribute to such payment, and the Company hereby waives and relinquishes any right of contribution it may have at any time against
      Indemnitee.

    
      5

      
        

    

    

    

    8.2.          The Company shall not enter into any settlement of any Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding) unless such settlement provides for a full
      and final release of all claims asserted against Indemnitee.

    

    

    8.3.          The Company hereby agrees to fully indemnify, hold harmless and exonerate Indemnitee from any claims for contribution which may be brought by officers, directors or employees of the Company other than
      Indemnitee who may be jointly liable with Indemnitee.

    

    

    9.          EXCLUSIONS.

    

    

    Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnification, advance expenses, hold harmless or exoneration payment in connection with any claim made against Indemnitee:

    

    

    (a)          for which payment has actually been received by or on behalf of Indemnitee under any insurance policy or other indemnity or advancement provision and which payment has not subsequently been returned, except
      with respect to any excess beyond the amount actually received under any insurance policy, contract, agreement, other indemnity or advancement provision or otherwise;

    

    

    (b)          for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act (or any successor
      thereof) or similar provisions of state statutory law or common law; or

    

    

    (c)          except as otherwise provided in Sections 14.5 and 14.6 hereof, prior to a Change in Control, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee,
      including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to
      its initiation or (ii) the Company provides the indemnification, hold harmless or exoneration payment, in its sole discretion, pursuant to the powers vested in the Company under applicable law.

    

    

    10.          ADVANCES OF EXPENSES; DEFENSE OF CLAIM.

    

    

    10.1.          Notwithstanding any provision of this Agreement to the contrary except for Section 27, and to the fullest extent not prohibited by applicable law, the Company shall pay the Expenses incurred by
      Indemnitee (or reasonably expected by Indemnitee to be incurred by Indemnitee within three months) in connection with any Proceeding within ten (10) days after the receipt by the Company of a statement or statements requesting such advances from time
      to time, prior to the final disposition of any Proceeding.  Advances shall be unsecured and interest free.  Advances shall be made without regard to Indemnitee’s ability to repay the Expenses and without regard to Indemnitee’s ultimate entitlement to
      be indemnified, held harmless or exonerated under the other provisions of this Agreement.  Advances shall include any and all reasonable Expenses incurred pursuing a Proceeding to enforce this right of advancement, including Expenses incurred
      preparing and forwarding statements to the Company to support the advances claimed.  To the fullest extent required by applicable law, such payments of Expenses in advance of the final disposition of the Proceeding shall be made only upon the
      Company’s receipt of an undertaking, by or on behalf of Indemnitee, to repay the advance to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company under the provisions of this Agreement, the
      Charter, the Bylaws of the Company, applicable law or otherwise. This Section 10.1 shall not apply to any claim made by Indemnitee for which an indemnification, hold harmless or exoneration payment is excluded pursuant to Section 9.

    

    

    10.2.          The Company will be entitled to participate in the Proceeding at its own expense.

    

    

    10.3.          The Company shall not settle any action, claim or Proceeding (in whole or in part) which would impose any Expense, judgment, fine, penalty or limitation on Indemnitee without Indemnitee’s prior written
      consent.

    
      6

      
        

    

    

    

    11.          PROCEDURE FOR NOTIFICATION AND APPLICATION FOR INDEMNIFICATION.

    

    

    11.1.          Indemnitee agrees to notify promptly the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter
      which may be subject to indemnification, hold harmless or exoneration rights, or advancement of Expenses covered hereunder.  The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to
      Indemnitee under this Agreement, or otherwise.

    

    

    11.2.          Indemnitee may deliver to the Company a written application to indemnify, hold harmless or exonerate Indemnitee in accordance with this Agreement.  Such application(s) may be delivered from time to time
      and at such time(s) as Indemnitee deems appropriate in his or her sole discretion.  Following such a written application for indemnification by Indemnitee, Indemnitee’s entitlement to indemnification shall be determined according to Section 12.1
      of this Agreement.

    

    

    12.          PROCEDURE UPON APPLICATION FOR INDEMNIFICATION.

    

    

    12.1.          A determination, if required by applicable law, with respect to Indemnitee’s entitlement to indemnification shall be made in the specific case by one of the following methods, which shall be at the
      election of Indemnitee:  (i) by a majority vote of the Disinterested Directors, even if less than a quorum of the Board (ii) by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee; or (iii) by vote
      of the stockholders.  The Company promptly will advise Indemnitee in writing with respect to any determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been
      denied.  If it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination.  Indemnitee shall reasonably cooperate with the person, persons or entity making such
      determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from
      disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination.  Any costs or Expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or
      entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby agrees to indemnify and to hold Indemnitee harmless therefrom.

    

    

    12.2.          In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12.1 hereof, the Independent Counsel shall be selected as provided in this
      Section 12.2.  The Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board), and Indemnitee shall give written notice to the Company advising it of the identity of the
      Independent Counsel so selected and certifying that the Independent Counsel so selected meets the requirements of “Independent Counsel” as defined in Section 2 of this Agreement.  If
      the Independent Counsel is selected by the Board, the Company shall give written notice to Indemnitee advising him or her of the identity of the Independent Counsel so selected and certifying that the Independent Counsel so selected meets the
      requirements of “Independent Counsel” as defined in Section 2 of this Agreement.  In either event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such
      written notice of selection shall have been received, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent
      Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the
      factual basis of such assertion.  Absent a proper and timely objection, the person so selected shall act as Independent Counsel.  If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent
      Counsel unless and until such objection is withdrawn or a court of competent jurisdiction has determined that such objection is without merit.  If, within twenty (20) days after submission by Indemnitee of a written request for indemnification
      pursuant to Section 11.2 hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Delaware Court for resolution of any objection which shall have been made by the Company
      or Indemnitee to the other’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the Delaware Court, and the person with respect to whom all objections are so resolved or the person so appointed
      shall act as Independent Counsel under Section 12.1 hereof.  Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 14.1 of this Agreement, Independent Counsel shall be discharged and relieved of any
      further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).

    
      7

      
        

    

    

    

    12.3.          The Company agrees to pay the reasonable fees and expenses of Independent Counsel and to fully indemnify and hold harmless such Independent Counsel against any and all Expenses, claims, liabilities and
      damages arising out of or relating to this Agreement or its engagement pursuant hereto.

    

    

    13.          PRESUMPTIONS AND EFFECT OF CERTAIN PROCEEDINGS.

    

    

    13.1.          In making a determination with respect to entitlement to indemnification hereunder, the person, persons or entity making such determination shall presume that Indemnitee is entitled to indemnification
      under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 11.2 of this Agreement, and the Company shall have the burden of proof to overcome that presumption in connection with the making by any
      person, persons or entity of any determination contrary to that presumption.  Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this
      Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met
      such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.

    

    

    13.2.          If the person, persons or entity empowered or selected under Section 12 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within
      thirty (30) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement
      by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a final judicial determination that any or all such
      indemnification is expressly prohibited under applicable law; provided, however, that such 30-day period may be extended for a reasonable time, not to exceed an additional fifteen (15) days, if the person, persons or entity making the determination
      with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto.

    

    

    13.3.          The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise
      expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed
      to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.

    

    

    13.4.          For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of the Enterprise, including
      financial statements, or on information supplied to Indemnitee by the directors, manager or officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise, its Board, any committee of the Board or any
      director, trustee, general partner, manager or managing member, or on information or records given or reports made to the Enterprise, its Board, any committee of the Board or any director, trustee, general partner, manager or managing member, by an
      independent certified public accountant or by an appraiser or other expert selected by the Enterprise, its Board, any committee of the Board or any director, trustee, general partner, manager or managing member.  The provisions of this Section
        13.4 shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed or found to have met the applicable standard of conduct set forth in this Agreement.

    

    

    13.5.          The knowledge and/or actions, or failure to act, of any other director, officer, trustee, general partner, manager, managing member, fiduciary, agent or employee of the Enterprise shall not be imputed to
      Indemnitee for purposes of determining the right to indemnification under this Agreement.

    
      8

      
        

    

    

    

    14.          REMEDIES OF INDEMNITEE.

    

    

    14.1.          In the event that (i) a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses, to the
      fullest extent permitted by applicable law, is not timely made pursuant to Section 10 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 12.1 of this Agreement within
      thirty (30) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Sections 5, 6, 7 or the last sentence of Section 12.1 of this Agreement within
      ten (10) days after receipt by the Company of a written request therefor, (v) a contribution payment is not made in a timely manner pursuant to Section 8 of this Agreement, (vi) payment of indemnification pursuant to Section 3 or 4
      of this Agreement is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, or (vii) payment to Indemnitee pursuant to any hold harmless or exoneration rights under this Agreement or
      otherwise is not made in accordance with this Agreement within ten (10) days after receipt by the Company of a written request therefor, Indemnitee shall be entitled to an adjudication by the Delaware Court to such indemnification, hold harmless,
      exoneration, contribution or advancement rights.  Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules and Mediation Procedures of the
      American Arbitration Association.  Except as set forth herein, the provisions of Delaware law (without regard to its conflict of laws rules) shall apply to any such arbitration.  The Company shall not oppose Indemnitee’s right to seek any such
      adjudication or award in arbitration.

    

    

    14.2.          In the event that a determination shall have been made pursuant to Section 12.1 of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration
      commenced pursuant to this Section 14 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination.  In any judicial proceeding or
      arbitration commenced pursuant to this Section 14, Indemnitee shall be presumed to be entitled to be indemnified, held harmless, exonerated to receive advances of Expenses under this Agreement and the Company shall have the burden of proving
      Indemnitee is not entitled to be indemnified, held harmless, exonerated and to receive advances of Expenses, as the case may be, and the Company may not refer to or introduce into evidence any determination pursuant to Section 12.1 of this
      Agreement adverse to Indemnitee for any purpose.  If Indemnitee commences a judicial proceeding or arbitration pursuant to this Section 14, Indemnitee shall not be required to reimburse the Company for any advances pursuant to Section 10
      until a final determination is made with respect to Indemnitee’s entitlement to indemnification (as to which all rights of appeal have been exhausted or lapsed).

    

    

    14.3.          If a determination shall have been made pursuant to Section 12.1 of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial
      proceeding or arbitration commenced pursuant to this Section 14, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection
      with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.

    

    

    14.4.          The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 14 that the procedures and presumptions of this Agreement are not valid,
      binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.

    

    

    14.5.          The Company shall indemnify and hold harmless Indemnitee to the fullest extent permitted by law against all Expenses and, if requested by Indemnitee, shall (within ten (10) days after the Company’s receipt
      of such written request) pay to Indemnitee, to the fullest extent permitted by applicable law, such Expenses which are incurred by Indemnitee in connection with any judicial proceeding or arbitration brought by Indemnitee (i) to enforce his or her
      rights under, or to recover damages for breach of, this Agreement or any other indemnification, hold harmless, exoneration, advancement or contribution agreement or provision of the Charter, or the Company’s Bylaws now or hereafter in effect; or (ii)
      for recovery or advances under any insurance policy maintained by any person for the benefit of Indemnitee, regardless of the outcome and whether Indemnitee ultimately is determined to be entitled to such indemnification, hold harmless or exoneration
      right, advancement, contribution or insurance recovery, as the case may be (unless such judicial proceeding or arbitration was not brought by Indemnitee in good faith).

    
      9

      
        

    

    

    

    14.6.          Interest shall be paid by the Company to Indemnitee at the legal rate under Delaware law for amounts which the Company indemnifies, holds harmless or exonerates, or advances, or is obliged to indemnify,
      hold harmless or exonerate or advance for the period commencing with the date on which Indemnitee requests indemnification, to be held harmless, exonerated, contribution, reimbursement or advancement of any Expenses and ending with the date on which
      such payment is made to Indemnitee by the Company.

    

    

    15.          SECURITY.

    

    

    Notwithstanding anything herein to the contrary except for Section 27, to the extent requested by Indemnitee and approved by the Board, the Company may at any time and from time to time provide security to Indemnitee for the Company’s
      obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral.  Any such security, once provided to Indemnitee, may not be revoked or released without the prior written consent of Indemnitee.

    

    

    16.          NON-EXCLUSIVITY; SURVIVAL OF RIGHTS; INSURANCE; SUBROGATION.

    

    

    16.1.          The rights of Indemnitee as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Charter, the Bylaws, any
      agreement, a vote of stockholders or a resolution of directors, or otherwise.  No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any
      Proceeding (regardless of when such Proceeding is first threatened, commenced or completed) arising out of, or related to, any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. 
      To the extent that a change in applicable law, whether by statute or judicial decision, permits greater indemnification, hold harmless or exoneration rights or advancement of Expenses than would be afforded currently under the Charter, the Bylaws or
      this Agreement, then this Agreement (without any further action by the parties hereto) shall automatically be deemed to be amended to require that the Company indemnify Indemnitee to the fullest extent permitted by law.  No right or remedy herein
      conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. 
      The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.

    

    

    16.2.          The DGCL, the Charter and the Bylaws permit the Company to purchase and maintain insurance or furnish similar protection or make other arrangements including, but not limited to, providing a trust fund,
      letter of credit, or surety bond (“Indemnification Arrangements”) on behalf of Indemnitee against any liability asserted against him or her or incurred by or on behalf of him or her or in
      such capacity as a director, officer, employee or agent of the Company, or arising out of his or her status as such, whether or not the Company would have the power to indemnify him or her against such liability under the provisions of this Agreement
      or under the DGCL, as it may then be in effect.  The purchase, establishment, and maintenance of any such Indemnification Arrangement shall not in any way limit or affect the rights and obligations of the Company or of Indemnitee under this Agreement
      except as expressly provided herein, and the execution and delivery of this Agreement by the Company and Indemnitee shall not in any way limit or affect the rights and obligations of the Company or the other party or parties thereto under any such
      Indemnification Arrangement.

    

    

    16.3.          To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, trustees, partners, managers, managing members, fiduciaries, employees, or
      agents of the Company or of any other Enterprise which such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for
      any such director, officer, trustee, partner, managers, managing member, fiduciary, employee or agent under such policy or policies.  If, at the time the Company receives notice from any source of a Proceeding as to which Indemnitee is a party or a
      participant (as a witness or otherwise), the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such Proceeding to the insurers in accordance with the procedures set forth in the respective
      policies.  The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.

    
      10

      
        

    

    

    

    16.4.          In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and
      take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

    

    

    16.5.          The Company’s obligation to indemnify, hold harmless, exonerate or advance expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, trustee, partner,
      manager, managing member, fiduciary, employee or agent of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification, hold harmless or exoneration payments or advancement of expenses from such Enterprise. 
      Notwithstanding any other provision of this Agreement to the contrary except for Section 27, (i) Indemnitee shall have no obligation to reduce, offset, allocate, pursue or apportion any indemnification, hold harmless, exoneration,
      advancement, contribution or insurance coverage among multiple parties possessing such duties to Indemnitee prior to the Company’s satisfaction and performance of all its obligations under this Agreement, and (ii) the Company shall perform fully its
      obligations under this Agreement without regard to whether Indemnitee holds, may pursue or has pursued any indemnification, advancement, hold harmless, exoneration, contribution or insurance coverage rights against any person or entity other than the
      Company.

    

    

    17.          DURATION OF AGREEMENT.

    

    

    All agreements and obligations of the Company contained herein shall continue during the period Indemnitee serves as a director or officer of the Company or as a director, officer, trustee, partner, manager, managing member, fiduciary, employee or
      agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other Enterprise which Indemnitee serves at the request of the Company and shall continue thereafter so long as Indemnitee shall be subject to any possible
      Proceeding (including any rights of appeal thereto and any Proceeding commenced by Indemnitee pursuant to Section 14 of this Agreement) by reason of his or her Corporate Status, whether or not he or she is acting in any such capacity at the
      time any liability or expense is incurred for which indemnification or advancement can be provided under this Agreement.

    

    

    18.          SEVERABILITY.

    

    

    If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever:  (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, without
      limitation, each portion of any Section, paragraph or sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or
      impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the
      parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section, paragraph or sentence of this Agreement containing any such provision held to be invalid, illegal or
      unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.

    

    

    19.          ENFORCEMENT AND BINDING EFFECT.

    

    

    19.1.          The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director, officer or key
      employee of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director, officer or key employee of the Company.

    

    

    19.2.          Without limiting any of the rights of Indemnitee under the Charter or Bylaws of the Company as they may be amended from time to time, this Agreement constitutes the entire agreement between the parties
      hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof.

    
      11

      
        

    

    

    

    19.3.          The indemnification, hold harmless, exoneration and advancement of expenses rights provided by or granted pursuant to this Agreement shall be binding upon and be enforceable by the parties hereto and their
      respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), shall continue as to an Indemnitee who has ceased to
      be a director, officer, employee or agent of the Company or a director, officer, trustee, general partner, manager, managing member, fiduciary, employee or agent of any other Enterprise at the Company’s request, and shall inure to the benefit of
      Indemnitee and his or her spouse, assigns, heirs, devisees, executors and administrators and other legal representatives.

    

    

    19.4.          The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all or a substantial part, of the business and/or assets
      of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such
      succession had taken place.

    

    

    19.5.          The Company and Indemnitee agree herein that a monetary remedy for breach of this Agreement, at some later date, may be inadequate, impracticable and difficult of proof, and further agree that such breach
      may cause Indemnitee irreparable harm.  Accordingly, the parties hereto agree that Indemnitee may enforce this Agreement by seeking, among other things, injunctive relief and/or specific performance hereof, without any necessity of showing actual
      damage or irreparable harm and that by seeking injunctive relief and/or specific performance, Indemnitee shall not be precluded from seeking or obtaining any other relief to which he or she may be entitled.  The Company and Indemnitee further agree
      that Indemnitee shall be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary injunctions and permanent injunctions, without the necessity of posting bonds or other undertaking in connection
      therewith.  The Company acknowledges that in the absence of a waiver, a bond or undertaking may be required of Indemnitee by a Court of competent jurisdiction and the Company hereby waives any such requirement of such a bond or undertaking.

    

    

    20.          MODIFICATION AND WAIVER.

    

    

    No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the parties hereto.  No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other
      provisions of this Agreement nor shall any waiver constitute a continuing waiver.

    

    

    21.          NOTICES.

    

    

    All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given (i) if delivered by hand and receipted for by the party to whom said notice or other communication shall
      have been directed, on such delivery, or (ii) if mailed by certified or registered mail with postage prepaid, on the third (3rd) business day after the date on which it is so mailed:

    

    

    (a)          If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide in writing to the Company.

    

    

    (b)          If to the Company, to:

    

    

    Fortistar Sustainable Solutions Corp.

    One North Lexington Avenue

    White Plains, New York 10601

    Attn: Thomas J. Kelly

    

    

    With a copy, which shall not constitute notice, to:

    

    

    Weil, Gotshal & Manges LLP

    767 Fifth Avenue

    New York, NY 10153

    Attn: Alexander D. Lynch, Esq.

    

    

    or to any other address as may have been furnished to Indemnitee in writing by the Company.

    
      12

      
        

    

    

    

    22.          APPLICABLE LAW AND CONSENT TO JURISDICTION.

    

    

    This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules.  Except with respect to any arbitration
      commenced by Indemnitee pursuant to Section 14.1 of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally:  (a) agree that any action or proceeding arising out of or in connection with this Agreement shall be
      brought only in the Delaware Court and not in any other state or federal court in the United States of America or any court in any other country; (b) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or
      proceeding arising out of or in connection with this Agreement; (c) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court; and (d) waive, and agree not to plead or to make, any claim that any such action or
      proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum, or is subject (in whole or in part) to a jury trial.

    

    

    23.          IDENTICAL COUNTERPARTS.

    

    

    This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement.  Only one such counterpart signed by the party
      against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

    

    

    24.          MISCELLANEOUS.

    

    

    The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

    

    

    25.          PERIOD OF LIMITATIONS.

    

    

    No legal action shall be brought and no cause of action shall be asserted by or in the right of the Company against Indemnitee, Indemnitee’s spouse, heirs, executors or personal or legal representatives after the expiration of two years from the
      date of accrual of such cause of action, and any claim or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such two-year period; provided, however, that if any
      shorter period of limitations is otherwise applicable to any such cause of action such shorter period shall govern.

    

    

    26.          ADDITIONAL ACTS.

    

    

    If for the validation of any of the provisions in this Agreement any act, resolution, approval or other procedure is required, the Company undertakes to cause such act, resolution, approval or other procedure to be affected or adopted in a manner
      that will enable the Company to fulfill its obligations under this Agreement.

    

    

    27.          WAIVER OF CLAIMS TO TRUST ACCOUNT.

    

    

    Indemnitee hereby agrees that it does not have any right, title, interest or claim of any kind (each, a “Claim”) in or to any monies in the trust account established in connection with
      the Company’s initial public offering for the benefit of the Company and holders of shares issued in such offering, and hereby waives any Claim it may have in the future as a result of, or arising out of, any services provided to the Company and will
      not seek recourse against such trust account for any reason whatsoever.

    

    

    [SIGNATURE PAGE FOLLOWS]

    
      13

      
        

    

    

    

    IN WITNESS WHEREOF, the parties hereto have caused this Indemnity Agreement to be signed as of the day and year first above written.

    

    	 	
            FORTISTAR SUSTAINABLE SOLUTIONS CORP.

          
	 	 	 
	 	
            By:

          	 
	 	 	
            Name:

          
	 	 	
            Title:

          
	 	 	 
	 	
            INDEMNITEE:

          
	 	 	 
	 	
            By:

          	 
	 	 	
            Name:

          
	 	 	
            Title:

          

    

    

    
      [Signature Page to Indemnity Agreement]

    

    
      
        

    

     

    

    ***

    

    

    Not Part of Form of Indemnity Agreement

    

    

    ***

    

    

    The following officers and directors of the Company separately executed the foregoing Form of Indemnity Agreement on January 29, 2021:

    

    

    Mark S. Comora

    

    

    Nadeem Nisar

    

    

    Charles D. Bryceland

    

    

    Jonathan Maurer

    

    

    Scott Contino

    

    

    Thomas J. Kelly

    

    

    George Coyle

    

    

    William D. Lese

    

    

    Mark M. LittleExhibit 10.1

 

 

 

Managing Director Service Agreement

 

 

 

entered into between

 

 

 

 

 

Panoptes Pharma Ges.m.b.H. (FN 399293 x),

 

Reisnerstraße 34/1, 1030 Vienna,

 

(hereinafter "Panoptes"
or "Company"),

 

 

 

 

 

and

 

 

 

 

 

Dr. Franz Obermayr

 

(hereinafter "Managing Director")

 

 

 

 

 

(together "Parties"; each
also "Party")

 

 

 

 

 

as follows:

 

 

 

    

    2 

    

 

PREAMBEL

 

The managing director is a founding shareholder
of Panoptes and has represented the company independently since 19 July 2013. He was appointed as managing director in the articles
of association for the duration of his position as shareholder.

 

The Managing Director's activities are
based on the Managing Director-Service Agreement concluded between him and the company on January 27, 2015, last amended by agreement
dated July 9, 2019 ("Managing Director-Service Agreement"). The Managing Director-Service Agreement was entered into
for the duration of Dr. Obermayr's appointment as managing director of the Company.

 

Upon execution of the share and purchase
agreement between EyeGate Pharmaceuticals, Inc, registered in the State of Delaware, reg. no. 3873818, with its business address
at 271 Waverley Oaks Road, Suite 108 Waltham, MA 02452 ("EyeGate") as purchaser of all shares in Panoptes (and thus future
sole shareholder) and the former shareholders of Panoptes as sellers of all their shares in Panoptes, Dr. Obermayr ceases to be
a shareholder and automatically also a director of the Company. In order to maintain continuity in the management of the Company,
the former shareholders decided prior to the signing of the share and purchase agreement, in consultation with EyeGate, to extend
Dr. Obermayr's function as managing director for an indefinite period of time, despite the transfer of his share in the Company.

 

Against this background, EyeGate and the
Managing Director have agreed to amend the Managing Director-Service Agreement as follows:

 

		1.	Rights and duties as managing directors

 

		1.1	The Managing Director shall conduct the business of the Company in accordance with the law, the
Company's articles of association, the rules of procedure for the management, the resolutions and instructions of the shareholders
and the provisions of this Managing Director's Service Agreement ("Agreement") with the due care of a prudent businessman
and for the benefit of the Company.

 

		1.2	The Managing Director shall place all his manpower, professional knowledge and experience without
restriction at the Company's disposal.

 

		2.	Management and power of representation

 

		2.1	The Managing Director's management and power of representation is based on the statutory provisions,
the provisions of the articles of association and shareholders' resolutions. The prior approval of the shareholders' meeting must
be obtained for the execution of legal transactions which go beyond the ordinary business operations of the Company or which are
made dependent on the approval of the shareholders' meeting by law, the articles of association and/or the rules of procedure for
the management.

 

		2.2	Any other regulation of the power of representation or the extension of transactions requiring
approval by resolution of the shareholders' meeting is reserved.

  

    

    3 

    

 

		3.	Remuneration

 

		3.1	The Managing Director receives a fixed annual salary of EUR 214,876.03 (Euro two hundred and
fourteen thousand eight hundred and seventy-six point three) gross, payable in fourteen equal monthly amounts. This results in
a fixed monthly salary of EUR 15,348.29 (Euro fifteen thousand three hundred and forty-eight point twenty-nine) gross. The
13th monthly salary is paid together with the remuneration for the month of June, the 14th monthly salary together with the remuneration
for the month of November. The monthly amount paid out regularly includes a basic salary of EUR 7,603.31 (Euro seven thousand
six hundred and three point thirty-one) gross for normal working hours.

 

		3.2	The remuneration pursuant to section 3.1 also covers services provided by the Managing Director
which exceed the normal working hours applicable to employees of the Company (e.g. overtime, work on Sundays and public holidays).
It is understood that the Managing Director will provide such additional services if required.

 

		3.3	The Company shall be entitled to withhold and pay the social security contributions and taxes payable
by the Managing Director. The resulting net amount shall be transferred to an account to be specified by the Managing Director
and a corresponding statement of account shall be sent to the Managing Director.

 

		3.4	The Managing Director shall be reimbursed for travel expenses and other out-of-pocket expenses
incurred in connection with the performance of the obligations under this Agreement in a reasonable amount in accordance with the
corresponding tax regulations. The Managing Director shall substantiate his expenses to the extent that receipts are usually provided.
In all other cases, personal receipts (e.g. telephone, tips) are sufficient, provided they are recognised by the tax authorities.

 

		4.	Bonus

 

	4.1	The general meeting of the Company may, in its absolute
discretion, award the Managing Director a "Discretionary bonus" of up to 25% (twenty-five per cent) of his fixed annual
salary for each fiscal year. Payment of any "Discretionary bonus" shall be made by 31st (thirty-first) March of the
following fiscal year.

 

		4.2	The Managing Director shall furthermore receive a one-off "Retention Bonus" for the fiscal
year 2021 amounting to 40% (forty percent) of his fixed annual salary. The "Retention Bonus" shall in principle be paid
in two equal instalments. One half shall be paid together with the remuneration for the month of June 2021, the other half together
with the remuneration for the month of December 2021. If Panoptes is terminating the Agreement without good cause before the end
of 2021, the Managing Director is entitled to receive the full amount of the "Retention Bonus".

 

		5.	Employee Pension Fund

 

The provisions
of the Company Employee and Self-Employment Pension Act ("BMSVG") apply to the contractual relationship in question.
The corresponding contributions are paid to the following employee pension fund: Niederösterreichische Vorsorgekasse AG (PVK
guide number 71700), Neue Herrengasse 10, 3100 St. Pölten.

 

    

    4 

    

 

		6.	Accident insurance, D&O insurance

 

	6.1	The Company will take out accident, occupational disability
and dread disease insurance for the Managing Director for the duration of this Agreement at market conditions.

 

	6.2	The Managing Director is entitled to designate the
beneficiary or beneficiaries in the event of death.

 

	6.3	The Company will also take out a financial loss liability
insurance for members of executive bodies (D&O insurance) for the Managing Director at market conditions.

 

		7.	Vacation, obstructions to work

 

		7.1	The Managing Director is entitled to 25 working days of vacation per holiday year. The holiday
year corresponds to the calendar year. The timing of the vacation is to be determined taking into account the business interests
of the Company and in consultation with the other managing directors. If there is no other managing director, a consultation with
the shareholders of the Company will take place.

 

		7.2	If the Managing Director is unable to take the vacation or cannot take it completely within the
holiday year for business or personal reasons, he shall, if possible, consume the vacation by December, 31 of the following year.
In all other respects, the expiry provisions of the Holiday Act (Urlaubsgesetz) shall apply.

 

		7.3	If the Managing Director is prevented from performing his services due to illness or accident,
he must notify the Company immediately. In case of illness or incapacity to work, the monthly salary shall continue to be paid
pursuant to section 8 Austrian Employee Act (Angestelltengesetz, AngG).

 

		8.	Non-competition clause

 

		8.1	The Managing Director is subject to the non-competition clause of § 7 Austrian Employee
Act (Angestelltengesetz) and § 24 Limited Liability Companies Act (Gesetz betreffend Gesellschaften mit beschränkter
Haftung, GmbHG). This prohibits the Managing Director from doing business in the Company's line of business for his own account
or for the account of a third party or from participating in a company in the same line of business as a personally liable partner
or from accepting a position on the management board, supervisory board or as managing director without the written consent of
the Company, which is granted by resolution of the shareholders' meeting or shareholders' circular resolution.

 

In the event
of a violation, the Company can demand compensation for damages or instead demand that the transactions made for the account of
the Managing Director be regarded as concluded for the Company's account. With regard to transactions concluded for the account
of third parties, the Company may request the surrender of the remuneration received for this purpose or the assignment of the
claim to the remuneration.

 

    

    5 

    

The right to
dismiss the Managing Director prematurely and to dissolve the Agreement due to a violation of the non-compete clause remains unaffected
(section 24 (3) GmbHG).

 

		8.2	In addition to the non-competition clause of section 24 GmbHG, the Managing Director is prohibited
from carrying out any activity against payment other than the activity stated in this Agreement without the written consent of
the Company, which is granted by resolution of the shareholders' meeting or shareholders' circular resolution, even if the activity
is not competitive.

 

		8.3	The mere acquisition of securities for the exclusive purpose of personal investment is permitted
as long as the shareholding in the respective company does not exceed 5 (five) % and this shareholding does not involve any entrepreneurial
influence or any personal obligation or liability of the Managing Director that could be detrimental to the performance of its
functions in the Company. A capital participation in companies which are to be regarded as competitors of the Company are, however,
not permitted. Excluded from this is the capital participation of the Managing Director in EyeGate.

 

		8.4	In his work for the Company, the Managing Director is obliged to put the Company's interests and
the Company's wellbeing before its own interests. Therefore, the Managing Director may not conclude any transactions in the name
of the Company without the written consent of the Company, which is granted by resolution of the shareholders' meeting or shareholders'
circular resolution, where either the Managing Director himself or a close relative within the meaning of § 32 Insolvency
Act (Insolvenzordnung, IO) of the Managing Director or a company close to the Managing Director or a close relative within
the meaning of § 32 IO of the Managing Director has an own economic interest in the conclusion of such transactions.

 

		8.5	The Managing Director is also prohibited from competing with the Company for a period of 12 months
after the end of this Agreement ("post-contractual non-competition clause").

 

This post-contractual non-competition
clause refers:

 

		–	materially to the area of research and development on DHODH inhibitors and the field of cross-linked
hyaluronic acids in ophthalmology, and

 

		–	geographically to the entire area of activity of the Company at the time this Agreement ends.

 

The material and geographical
scope of the non-competition clause are collectively referred to as the "Business Area".

 

		8.6	The post-contractual non-competition clause includes any competitive activity in the Business Area
of the Company, whether directly or indirectly, self-employed, as a freelancer, employee-like or as an employee, through the establishment
of or participation in a competitive company, through advisory activities or in any other way.

 

    

    6 

    

		8.7	The Managing Director further undertakes not to entice away employees from the Company, its affiliates
and its direct parent company (together "Group Companies"), either directly or indirectly, for a period of 12 months
after termination of this Agreement, for example by using personnel consulting companies or other third parties, or to cause them
in any other way to terminate their employment relationship with an employer belonging to the Group Companies.

 

		8.8	In case the Managing Director violates the post-contractual non-competition clause, he shall be
obliged to pay a contractual penalty in the amount of six times the last net monthly remuneration due (excluding special payments)
per violation.

 

In case the act of infringement
consists of a capital participation in a competitive company or of entering into a continuing obligation (e.g. employment, service,
commercial agent or consulting relationship), the contractual penalty shall be forfeited for each month or part thereof during
which the capital participation or the continuing obligation exists (continuous infringement). Several acts of infringement shall
each trigger separate contractual penalties, if necessary also several times within one month. If, on the other hand, individual
acts of infringement occur as part of a continuing infringement, they are included in the penalty forfeited for the continuing
infringement.

 

		9.	Confidentiality

 

	9.1	The Managing Director is obliged to maintain strictest
secrecy towards third parties about all business, operational or technical information and processes which are entrusted to him
or otherwise become known to him and which concern the Company and are of an internal or confidential nature, in particular information
about employees, sources of supply, customers and other contractual partners, on the conclusion of contracts and conditions, on
economic, technical, operational, fiscal and personal relationships, on business papers and business plans of all kinds as well
as on internal Company matters. The Managing Director undertakes to treat as confidential all items received and becoming known
to him that are legally protected or contain business or trade secrets or are designated as confidential, even after the end of
the Agreement, unless they are publicly known without breach of the duty of confidentiality. The Managing Director stores and
secures objects in such a way that access by third parties is excluded. Excluded from the confidentiality obligation is an exchange
of information with (i) consultants who are subject to a professional confidentiality obligation and (ii) employees or contractual
partners of the Company, as far as such an exchange of information is necessary for the implementation of agreed business relations
in the interest of the Company.

 

	9.2	Business and operational documents of all kinds (such
as deeds, contracts, notes, correspondence, expert opinions, procedures, calculations, etc., whether original, carbon copy or
draft), including personal records on business matters, may only be used for business purposes of the management of the Company.
In particular, it is prohibited to provide third parties with copies, photocopies or extracts of business-related cost calculations,
statistics, drawings and similar documents with confidential contents unless this is necessary for the pursuit of the business
purpose.

 

    

    7 

    

 

		10.	Term of agreement

 

		10.1	This Agreement shall apply from December 18, 2020, shall replace all previous agreements and shall
be concluded for an indefinite period. The Agreement may be terminated by the Managing Director and the Company by giving 3 (three)
months' notice to the end of a calendar month ("ordinary termination"). The right of the Parties to terminate the Agreement
with immediate effect for good cause remains unaffected.

 

		10.2	The Managing Director may be dismissed as Managing Director of the Company at any time and without
good cause (section 16 GmbHG). In the event of a dismissal without good cause, the shareholders must simultaneously terminate the
Agreement at the next possible termination date, observing the period of notice specified in section 10.1. If a dismissal is made
with good cause corresponding to one of the reasons listed in section 27 Employee Act or an equivalent reason, the shareholders
must simultaneously pronounce the dismissal of the Managing Director and thus terminate the Agreement with immediate effect.

 

		10.3	In the event of termination of the Agreement, the Managing Director is obliged to immediately return
in good order and condition all items of use and documents made available to him by the Company.

 

		11.	Patent / Copyrights

 

		11.1	The Managing Director assigns any service inventions within the meaning of section 7 (1) Patent
Act (Patentgesetz, PatG) to the Company for its sole disposal. The Managing Directors therefore undertakes to inform the
Company accordingly, at the latest at the time of the patentable development of the invention, to hand over to the Company the
necessary documents and to enable the sole use of the invention. The Company will declare within a period of four months whether
it claims the invention. If the Company rejects the invention or does not express its opinion within the agreed period, the rights
to the invention shall remain with the Managing Director.

 

		11.2	Until the patent application is filed, both parties shall obliged to maintain absolute secrecy.
In the event that the Company claims the invention, the Managing Director shall be entitled to and receive reasonable compensation
for the transfer of the invention made by him and for the granting of the right of use. Upon request of the Managing Director,
the Company will name the Managing Director as the inventor upon registration in the patent register.

 

		11.3	Furthermore, the Managing Director shall grant the Company all relevant rights of use for works
protected by copyright and created by him within the scope of his activities, in particular the right to reproduce, distribute,
exhibit, otherwise change or edit these works. The Company therefore has an exclusive right to use the works.

 

		12.	Forfeiture clause

 

All mutual claims
arising from this Agreement must be asserted in writing within 3 (three) months, otherwise they shall lapse. The period begins
with the knowledge of the reason for the claim, but at the earliest with the due date. If the other party rejects the claim in
writing, the claim shall expire within 3 (three) months after the first out-of-court assertion, unless it is asserted in court.

 

    

    8 

    

		13.	Final provisions

 

		13.1	Declarations made by the Company to the Managing Director shall be deemed validly made if they
are delivered to the last address notified by the Managing Director. This applies in particular to deliveries during vacations.

 

		13.2	There are no verbal side agreements. All amendments and/or supplements to this Agreement must be
made in writing in order to be legally effective; this also applies to any departure from the written form requirement by mutual
consent and approval by resolution of the shareholder Meeting.

 

		13.3	Should any provision of this Agreement be or become legally invalid, the validity of the remaining
provisions of the Agreement shall not be affected thereby. In this case, a legally permissible provision that is compatible with
the provisions of this Agreement shall apply, which comes closest to the economically pursued purpose of the invalid provisions.
This shall also apply mutatis mutandis to contractual loopholes.

 

		13.4	Unless otherwise provided for in the law on limited liability companies, the articles of association,
the rules of procedure for the management and this Agreement, the provisions of the Employee Act shall apply in their currently
valid version. It is stated that the Managing Director is not subject to the provisions of the Working Hours Act (Arbeitszeitgesetz)
and the Act on Suspension of Work (Arbeitsruhegesetz).

 

		13.5	All disputes arising under this Agreement shall be brought exclusively before the competent local
court in labour and social law matters.

 

		13.6	The Agreement is made in two copies. The Parties shall each receive one copy. In addition, an English
translation of the Agreement shall be provided for EyeGate. It is agreed that the German version shall be the binding and authoritative
version for all matters relating to the meaning or interpretation of the Agreement.

 

 

Vienna, December 18, 2020

 

	 	/s/ Dr. Franz Obermayr	 
	
	 	Dr. Franz Obermayr	 

 

 

Boston, December 18, 2020

 

 

 

on behalf of Panoptes Pharma Ges.m.b.H.
their sole shareholder:

 

EyeGate Pharmaceuticals, Inc.

 

 

	 	/s/ Stephen From	 
	
	 	Stephen From

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]